Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.
Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.
ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.
Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.
AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Aldeyra Therapeutics Inc.’s drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.
In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.